Burney Co. Decreases Stock Position in Prestige Consumer Healthcare Inc. $PBH

Burney Co. lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,810 shares of the company’s stock after selling 1,670 shares during the quarter. Burney Co.’s holdings in Prestige Consumer Healthcare were worth $544,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PBH. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after acquiring an additional 493,199 shares during the period. Invesco Ltd. boosted its holdings in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after acquiring an additional 261,537 shares during the period. Tributary Capital Management LLC purchased a new position in Prestige Consumer Healthcare in the 2nd quarter worth approximately $11,773,000. Goldman Sachs Group Inc. boosted its holdings in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after acquiring an additional 120,965 shares during the period. Finally, Neumeier Poma Investment Counsel LLC purchased a new position in Prestige Consumer Healthcare in the 1st quarter worth approximately $8,713,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $59.78 on Thursday. The business’s fifty day moving average price is $63.26 and its 200 day moving average price is $73.45. Prestige Consumer Healthcare Inc. has a 12-month low of $59.51 and a 12-month high of $90.04. The stock has a market capitalization of $2.94 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same quarter last year, the business earned $0.90 earnings per share. The business’s revenue for the quarter was down 6.6% compared to the same quarter last year. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a research note on Wednesday, September 24th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Finally, Oppenheimer reduced their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $87.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.